Nadolol (SQ-11725): Non-Selective Beta-Adrenergic Blocker for Cardiovascular Research

Executive Summary: Nadolol (SQ-11725) is a non-selective beta-adrenergic receptor blocker widely used in cardiovascular research models of hypertension, angina pectoris, and vascular headaches. It acts as a substrate for OATP1A2, impacting its pharmacokinetic distribution and transporter-mediated uptake (Sun et al., 2025). The compound demonstrates robust physicochemical stability when stored at -20°C. Nadolol's mechanism involves competitive inhibition of beta-adrenergic receptors, leading to reduced heart rate and myocardial contractility. APExBIO supplies Nadolol (BA5097) for research use only, not for diagnostic or therapeutic applications (APExBIO product page).

Biological Rationale

Nadolol (SQ-11725) is a non-selective beta-adrenergic receptor antagonist, targeting both β1 and β2 adrenergic receptors. These receptors are central to the regulation of cardiovascular physiology, including heart rate, contractility, and vascular tone (see detailed mechanism). Disruption of beta-adrenergic signaling is implicated in the pathogenesis of hypertension, angina pectoris, and vascular headaches (protocol guidance). Nadolol's oral bioavailability and OATP1A2-mediated transport allow it to model transporter-influenced pharmacokinetics in preclinical settings (Sun et al., 2025). Its defined activity profile makes it integral to studies dissecting beta-adrenergic signaling and cardiovascular disease mechanisms.

Mechanism of Action of Nadolol (SQ-11725)

Nadolol competitively inhibits beta-adrenergic receptors. As a non-selective antagonist, it binds to both β1 and β2 receptor subtypes, preventing endogenous catecholamines (e.g., norepinephrine, epinephrine) from activating downstream signaling cascades. This blockade reduces heart rate (negative chronotropy), decreases myocardial contractility (negative inotropy), and lowers cardiac output. Through these effects, Nadolol attenuates the sympathetic drive implicated in hypertension and angina pectoris. Additionally, Nadolol is a substrate for the organic anion transporting polypeptide 1A2 (OATP1A2), which modulates its cellular uptake and systemic distribution (Sun et al., 2025). This dual mechanism provides a unique tool for dissecting both receptor-level and transporter-mediated processes in cardiovascular research.

Evidence & Benchmarks

• Nadolol exhibits high affinity for both β1 and β2 adrenergic receptors, with Ki values in the low nanomolar range under physiological pH and temperature conditions (25°C, pH 7.4) (Sun et al., 2025).
• Oral administration in rodent models at doses of 1–10 mg/kg results in dose-dependent reductions in systolic blood pressure, with maximal effect observed at 2 hours post-dose (Nadolol: Mechanism).
• As an OATP1A2 substrate, Nadolol demonstrates altered plasma and tissue pharmacokinetics in models with transporter modulation, supporting its use in transporter-focused studies (Sun et al., 2025).
• Stability assays confirm Nadolol's structural integrity when stored at -20°C for up to 12 months, with <2% degradation detected by UHPLC-MS/MS (APExBIO).
• In preclinical angina models, Nadolol administration reduces the frequency and severity of provoked vascular headaches by at least 30% compared to vehicle (Protocol Insights).

Applications, Limits & Misconceptions

Nadolol (SQ-11725) is suited for:

• Modeling beta-adrenergic signaling blockade in hypertension and angina pectoris.
• Investigating transporter-mediated pharmacokinetics, especially OATP1A2 interactions.
• Assessing cardiovascular and headache models requiring robust, non-selective beta-blockade.

This article extends previous site resources by integrating recent transporter-PK findings from Sun et al. (2025), offering actionable benchmarks and clarifying the role of OATP1A2—details not exhaustively covered in earlier discussions on transporter-mediated PK. Where those articles focus on protocol or conceptual overviews, this page delivers atomic, cross-verified claims and stability guidelines.

Common Pitfalls or Misconceptions

• Nadolol is not selective for β1 over β2 adrenergic receptors; it equally inhibits both subtypes.
• It is not indicated for acute diagnostic or therapeutic use in humans; research use only.
• Long-term storage of solutions, especially at room temperature, leads to degradation; solid form must be stored at -20°C.
• OATP1A2 interactions may not model all human transporter scenarios due to interspecies differences.
• Not all cardiovascular models benefit from non-selective beta-blockade—disease context and endpoint must be verified.

Workflow Integration & Parameters

Compound Handling: Nadolol (SQ-11725) is supplied as a solid, molecular weight 309.40 (C17H27NO4). Store at -20°C. For solution preparation, use promptly; avoid prolonged storage to maintain efficacy (product page). For shipping, Blue Ice is used for small molecules; Dry Ice for modified nucleotides.

Experimental Application: Typical doses in rodent models range from 1–10 mg/kg, with oral or intraperitoneal administration. Monitor cardiovascular endpoints (e.g., blood pressure, heart rate) at defined intervals (e.g., 0.5, 2, 4, 8 hours post-dose). Include transporter modulation controls when studying OATP1A2-mediated effects (Sun et al., 2025).

Data Integration: Quantitate Nadolol and metabolites with validated UHPLC-MS/MS protocols. Cross-validate PK data with transporter expression analysis (e.g., qPCR, Western blot) to interpret variability (advanced workflow). This clarifies transporter influence, a nuance not fully detailed in earlier practical guides.

Related Resources: For extended troubleshooting, refer to Nadolol (SQ-11725) in Cardiovascular Disease Models: Application Protocols—this article adds stable transporter-PK integration and benchmarked storage parameters.

Conclusion & Outlook

Nadolol (SQ-11725) remains a cornerstone in cardiovascular disease research, providing robust, reproducible modulation of beta-adrenergic signaling and transporter-mediated kinetics. Its dual role as a non-selective beta-blocker and OATP1A2 substrate enables sophisticated modeling of pharmacodynamic and pharmacokinetic phenomena. Reliable supply from APExBIO and well-defined storage/handling protocols support its integration into translational research workflows. Future studies should leverage Nadolol’s transporter substrate status to further elucidate drug-drug interactions and tissue-specific pharmacokinetics, particularly in disease models with altered transporter expression.